Fair Value of Financial Assets and Liabilities (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2021

Dec. 31, 2020

Fair Value of Financial Assets and Liabilities (Tables) [Line Items]

Schedule of financial assets and liabilities measured at fair value on a recurring basis

	Fair Value Measurements as of March 31, 2021
	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents – money market funds	$	21,000	$	—	$	—	$	21,000
Convertible note receivable		—		—		4,763		4,763
	$	21,000	$	—	$	4,763	$	25,763
Liabilities:
Contingent consideration obligations	$	—	$	—	$	294,023	$	294,023
Preferred stock warrants		—		—		113,145		113,145
	$	—	$	—	$	407,168	$	407,168

	Fair Value Measurements as of December 31, 2020
	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents – money market funds	$	45,000	$	—	$	—	$	45,000
Convertible note receivable		—		—		4,715		4,715
	$	45,000	$	—	$	4,715	$	49,715
Liabilities:
Contingent consideration obligations	$	—	$	—	$	273,367	$	273,367
Preferred stock warrants		—		—		76,640		76,640
	$	—	$	—	$	350,007	$	350,007

	Fair Value Measurements as of December 31, 2020
	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents – money market funds	$	45,000	$	—	$	—	$	45,000
Convertible note receivable		—		—		4,715		4,715
	$	45,000	$	—	$	4,715	$	49,715
Liabilities:
Contingent consideration obligations		—		—		273,367		273,367
Preferred stock warrants		—		—		76,640		76,640
	$	—	$	—	$	350,007	$	350,007

	Fair Value Measurements as of December 31, 2019
	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents – money market funds	$	—	$	—	$	—	$	—
	$	—	$	—	$	—	$	—
Liabilities:
Contingent consideration obligations		—		—		328,933		328,933
	$	—	$	—	$	328,933	$	328,933

Schedule of reconciliation of contingent consideration obligations measured on a recurring basis

	Balance as of December 31, 2020		Net transfers in to (out of) Level 3		Purchases, settlements and other net		Fair value adjustments		Balance as of March 31, 2020
Liabilities:
Contingent consideration obligations	$	273,367	$	—	$	—	$	20,656	$	294,023

	Balance as of December 31, 2019		Net transfers in to (out of) Level 3		Purchases, settlements and other net		Fair value adjustments			Balance as of December 31, 2020
Liabilities:
Contingent consideration obligations	$	328,933	$	—	$	—	$	(55,566	)	$	273,367

	Balance as of December 31, 2019		Net transfers in to (out of) Level 3		Purchases, settlements and other net		Fair value adjustments			Balance as of December 31, 2020
Liabilities:
Contingent consideration obligations	$	328,933	$	—	$	—	$	(55,566	)	$	273,367

	Balance as of December 31, 2018		Net transfers in to (out of) Level 3		Purchases, settlements and other net			Fair value adjustments		Balance as of December 31, 2019
Liabilities:
Contingent consideration obligations	$	263,641	$	—	$	(3,575	)	$	68,867	$	328,933

Schedule of aggregate fair values of the company’s warrant liability

Balance as of December 31, 2019	$	—
Fair value of warrants issued in connection with Series B preferred stock sale		17,954
Issuance of warrant at fair value*		11,988
Loss recognized in earnings from change in fair value		46,698
Balance as of December 31, 2020	$	76,640

Balance as of December 31, 2020	$	76,640
Loss recognized in earnings from change in fair value		36,505
Balance as of March 31, 2021	$	113,145

Balance as of December 31, 2018	$	1,596
Loss recognized in earnings from change in fair value		4,226
Exercise or expiration of warrants		(5,822	)
Balance as of December 31, 2019	$	—
Balance as of December 31, 2019	$	—
Fair value of warrants issued in connection with Series B preferred stock sale		17,954
Issuance of warrant at fair value*		11,988
Loss recognized in earnings from change in fair value		46,698
Balance as of December 31, 2020	$	76,640

*        The warrants issued at fair value were immediately charged to expense (see Note 11).

Schedule of fair value of the warrants issued

	March 31, 2021			December 31, 2020
Fair value of common stock	$	3.55 – 6.95		$	3.20 – 5.34
Exercise price(a)	$	5.20		$	5.20
Term		2.05 – 3.88			0.33 – 1.33
Volatility		90	%		90	%
Risk-free interest rate		0.17% – 0.63%			0.09% – 0.10%

	March 31, 2021			December 31, 2020
Fair value of common stock	$	3.55 – 6.95		$	3.20 – 5.34
Exercise price(b)	$	5.79		$	5.79
Term		2.05 – 3.88			0.33 – 1.33
Volatility		90	%		90	%
Risk-free interest rate		0.17% – 0.63%			0.09% – 0.10%

(a)      The exercise price is the lower of $5.20 per share or eighty percent (80%) of either (i) the value attributed to one share of Series B Preferred Stock upon a consummation of a change of control or the closing of a strategic transaction or (ii) the price at which one (1) share of the common stock is sold to the public in an initial public offering. As amended on March 16, 2020, the warrants are exercisable on the first to occur of (a) March 16, 2025, (b) the consummation of the Company’s initial public offering, (c) the consummation of a change of control and (d) the closing of a strategic transaction pursuant to which the Company’s shareholders exchange their existing shares of capital stock in the Company for shares in a company whose shares are listed on a national stock exchange.

(b)      The warrants are exercisable at a price of $5.787 per share on the first to occur of (a) the 60-month anniversary of the date of issuance of the warrants, (b) the consummation of an agreement for a public exit event (c) the consummation of a change of control.

	IssuanceJanuary 9, 2020		December 31, 2020
Fair value of common stock	$3.06		$ 4.65
Exercise price(a)	$5.20		$5.20
Term	0.98 – 2.98		0.33 – 1.33
Volatility	60	%	90	%
Risk-free interest rate	1.53% – 1.58	%	0.09% – 0.10	%

	IssuanceMarch 16, 2020		December 31, 2020
Fair value of common stock	$2.66		$4.65
Exercise price(b)	$5.79		5.79
Term	0.79 – 2.79		0.33 – 1.33
Volatility	70	%	90	%
Risk-free interest rate	0.29% – 0.41	%	0.09% – 0.10	%

(a)      The exercise price is the lower of $5.20 per share or eighty percent (80%) of either (i) the value attributed to one share of Series B Preferred Stock upon a consummation of a change of control or the closing of a strategic transaction or (ii) the price at which one (1) share of the common stock is sold to the public in an initial public offering. As amended on March 16, 2020, the warrants are exercisable on the first to occur of (a) March 16, 2025, (b) the consummation of the Company’s initial public offering, (c) the consummation of a change of control and (d) the closing of a strategic transaction pursuant to which the Company’s shareholders exchange their existing shares of capital stock in the Company for shares in a company whose shares are listed on a national stock exchange.

(b)      The warrants are exercisable at a price of $5.787 per share on the first to occur of (a) the 60-month anniversary of the date of issuance of the warrants, (b) the consummation of an agreement for a public exit event (c) the consummation of a change of control.

Schedule of convertible note valuation model

	March 31, 2021			December 31, 2020
Face value	$	4,000		$	4,000
Coupon rate		12	%		12	%
Stock price	$	0.17		$	0.19
Term		0.25 – 0.35			0.6
Risk-free interest rate		0.05	%		0.09	%
Volatility		84	%		70	%

	IssuanceAugust 6, 2020			December 31, 2020
Face value	$	4,000		$	4,000
Coupon rate		12	%		12	%
Stock price	$	0.24		$	0.19
Term		1.0			0.6
Risk-free interest rate		0.14	%		0.09	%
Volatility		80	%		70	%

Gx Acquisition Corp [Member]

Fair Value of Financial Assets and Liabilities (Tables) [Line Items]

Schedule of fair value measured on recurring basis

Description	Level	March 31, 2021		December 31, 2020
Assets:
Marketable securities held in Trust Account	1	$	291,784,977	$	291,797,144
Liabilities:
Warrant Liability – Public Warrants	1		15,182,500		41,400,000
Warrant Liability – Private Placement Warrants	3		7,980,000		22,400,000

		As of December 31,
Description	Level	2020		2019
Assets:
Marketable securities held in Trust Account	1	$	291,797,144	$	290,594,540
Liabilities:
Warrant Liability – Public Warrants	1		41,400,000		11,500,000
Warrant Liability – Private Placement Warrants	2		22,400,000		5,670,000

Schedule of monte carlo simulation model for the private placement warrants and public warrants

Input	March 31, 2021			December 31, 2020
Risk-free interest rate		0.94	%		0.41	%
Trading days per year		250			250
Expected volatility		11.0	%		11.0	%
Exercise price	$	11.50		$	11.50
Stock Price	$	10.08		$	11.00

Input	December 31, 2020			December 31, 2019
Risk-free interest rate		0.41	%		1.73	%
Trading days per year		250			250
Expected volatility		16.0	%		5.0	%
Exercise price	$	11.50		$	11.50
Stock Price	$	11.00		$	9.95

Schedule of changes in the fair value of warrant liabilities

	Private Placement			Public			Warrant Liabilities
Fair value as of December 31, 2020	$	22,400,000		$	41,400,000		$	63,800,000
Change in valuation inputs or other assumptions		(14,420,000	)		(25,587,500	)		(40,007,500	)
Fair value as of March 31, 2021	$	7,980,000		$	15,812,500		$	23,792,500

	Private Placement			Public			Warrant Liabilities
Fair value as of December 31, 2018	$	—		$	—		$	—
Initial measurement on May 23, 2019		7,280,000			14,375,000			21,655,000
Change in valuation inputs or other assumptions		(1,610,000	)		(2,875,000	)		(4,485,000	)
Fair value as of December 31, 2019		5,670,000			11,500,000			17,170,000
Change in valuation inputs or other assumptions		16,730,000			29,900,000			46,630,000
Fair value as of December 31, 2020	$	22,400,000		$	41,400,000		$	63,800,000